EUCTR2011-001096-39-SK进行中（未招募）1 期
An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 4,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Adult (according to local legislation) male or female
- •- Chronic hepatitis C (CHC)
- •- Patients naïve to CHC treatment or patients who
- •received prior interferon (IFN) based therapy for CHC
- •for whom data on treatment received (type of therapy, dose, duration) and treatment outcome (i.e. rapid virological response [RVR], complete early virological response [cEVR], partial early virological response [pEVR], end of treatment response [EoT), sustained virological response [SVR], relapse, breakthrough, nonresponse) of prior therapy is available. In addition information on fibrosis stage prior to the previous treatment course is required.
- •- Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Co-infection with hepatitis B
- •- History or other evidence of decompensated liver
- •- History of major organ transplantation with an existing functional graft (including liver transplantation)
- •- End stage renal disease
研究者
相似试验
进行中（未招募）
不适用
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-013884-21-DEEnceladus Pharmaceuticals BV90
进行中（未招募）
1 期
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)EUCTR2009-013884-21-BEEnceladus Pharmaceuticals BV90
进行中（未招募）
不适用
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-013884-21-PLEnceladus Pharmaceuticals BV90
进行中（未招募）
1 期
An international multi-center, open-label study to evaluate safety, tolerability, biodistribution (distribution in the body), dosimetry (to calculate the radiation exposure of patients) and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor positive neuroendocrine tumours (NETs).euroendocrine tumors (NETs)MedDRA version: 21.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002867-41-DKIpsen Pharma55
进行中（未招募）
1 期
An international multi-center, open-label study to evaluate safety,tolerability, biodistribution (distribution in the body), dosimetry (tocalculate the radiation exposure of patients) and preliminary efficacy of177Lu-OPS201 for the therapy of somatostatin receptor positiveneuroendocrine tumours (NETs).EUCTR2015-002867-41-GBIpsen Pharma55